HK1060521A1 - Pharmaceuticals comprising the heat shock protein 10 (cpn 10) from my cobacterium tuberculosis. - Google Patents

Pharmaceuticals comprising the heat shock protein 10 (cpn 10) from my cobacterium tuberculosis.

Info

Publication number
HK1060521A1
HK1060521A1 HK04103573A HK04103573A HK1060521A1 HK 1060521 A1 HK1060521 A1 HK 1060521A1 HK 04103573 A HK04103573 A HK 04103573A HK 04103573 A HK04103573 A HK 04103573A HK 1060521 A1 HK1060521 A1 HK 1060521A1
Authority
HK
Hong Kong
Prior art keywords
cpn
pharmaceuticals
heat shock
shock protein
cobacterium tuberculosis
Prior art date
Application number
HK04103573A
Other languages
English (en)
Inventor
Anthony Robert Milnes Coates
Original Assignee
Helperby Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helperby Therapeutics Ltd filed Critical Helperby Therapeutics Ltd
Publication of HK1060521A1 publication Critical patent/HK1060521A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
HK04103573A 2000-11-17 2004-05-20 Pharmaceuticals comprising the heat shock protein 10 (cpn 10) from my cobacterium tuberculosis. HK1060521A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0028122.0A GB0028122D0 (en) 2000-11-17 2000-11-17 Method
PCT/GB2001/005084 WO2002040038A2 (en) 2000-11-17 2001-11-16 M. tuberculosis chaperonin 10 and uses thereof

Publications (1)

Publication Number Publication Date
HK1060521A1 true HK1060521A1 (en) 2004-08-13

Family

ID=9903393

Family Applications (2)

Application Number Title Priority Date Filing Date
HK04103315A HK1060970A1 (en) 2000-11-17 2004-05-12 The use of cpn60 from mycobacterium tuberculosis in preparing medicaments for allergic conditions and inflammatory diseases.
HK04103573A HK1060521A1 (en) 2000-11-17 2004-05-20 Pharmaceuticals comprising the heat shock protein 10 (cpn 10) from my cobacterium tuberculosis.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK04103315A HK1060970A1 (en) 2000-11-17 2004-05-12 The use of cpn60 from mycobacterium tuberculosis in preparing medicaments for allergic conditions and inflammatory diseases.

Country Status (15)

Country Link
US (2) US20040127438A1 (xx)
EP (3) EP1333841B1 (xx)
JP (5) JP2004525085A (xx)
AT (2) ATE355845T1 (xx)
AU (5) AU1511702A (xx)
CA (2) CA2429897A1 (xx)
CY (2) CY1105619T1 (xx)
DE (2) DE60127159D1 (xx)
DK (1) DK1333841T3 (xx)
ES (2) ES2585641T3 (xx)
GB (3) GB0028122D0 (xx)
HK (2) HK1060970A1 (xx)
NZ (2) NZ525858A (xx)
PT (1) PT1333841E (xx)
WO (3) WO2002040517A2 (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
AU2002952492A0 (en) 2002-11-06 2002-11-21 Cbio Limited Chaperonin 10 immunosuppression
AU2003277992B2 (en) * 2002-11-06 2008-07-10 Cbio Limited Chaperonin 10 immunosuppression
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
NZ548985A (en) * 2004-01-16 2010-02-26 Cbio Ltd Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion
EP1951282A4 (en) * 2005-10-20 2009-09-02 Cbio Ltd TREATMENT OF HYPERSENSITIVITY
AU2013205017B2 (en) * 2006-03-02 2014-05-01 Cbio Limited Regulation of immune responses by modulation of the function of antigen presenting cells
CA2644058C (en) * 2006-03-02 2016-08-09 Cbio Limited Regulation of immune responses by modulation of the function of antigen presenting cells
US8834895B2 (en) * 2007-03-21 2014-09-16 National Research Council Of Canada Use of Francisella tularensis for prevention and treatment of allergic airway disorders
GB0803369D0 (en) 2008-02-25 2008-04-02 Helperby Therapeutics Ltd Biological materials and uses thereof
GB201118201D0 (en) 2011-10-21 2011-12-07 Helperby Therapeutics Ltd Novel peptides
CN106581672A (zh) * 2015-10-15 2017-04-26 广东思峰生物科技有限责任公司 一种rhIL‑12用于治疗非活动性乙肝的药物组合物
CN107202894B (zh) * 2016-03-17 2019-02-22 广东体必康生物科技有限公司 Rv1078蛋白在诊断潜伏性/活动性肺结核中的用途
GB201700557D0 (en) 2017-01-12 2017-03-01 Peptinnovate Ltd Novel peptides
GB201700555D0 (en) * 2017-01-12 2017-03-01 Peptinnovate Ltd Method for the treatment of a relapsing-remitting condition
IL314861A (en) 2022-02-17 2024-10-01 Revolo Biotherapeutics Ltd A method for the production of a peptide derived from chaperonin 60.1
WO2023223015A1 (en) 2022-05-16 2023-11-23 Revolo Biotherapeutics Limited Methods and compositions for preventing or treating food allergies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780034A (en) * 1989-03-14 1998-07-14 Yeda Research And Development Co. Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus using heat shock protein determinents
CA2176948C (en) * 1993-11-30 2007-05-15 Halle Morton Chaperonin 10
PT731811E (pt) * 1993-11-30 2005-04-29 Univ Queensland Chaperonina 10
CA2185826C (en) * 1994-03-21 2007-06-19 Stephen Mark Anderton Peptide fragments of microbial stress proteins and pharmaceutical composition made thereof for the treatment and prevention of inflammatory diseases
IT1271074B (it) * 1994-11-21 1997-05-26 Italfarmaco Spa Peptidi ad attivita' antiinfiammatoria
CA2272536A1 (en) * 1996-11-26 1998-06-04 Stressgen Biotechnologies Corp. Immune responses using compositions containing stress proteins
FR2766191B1 (fr) * 1997-07-21 2000-11-10 Ifremer Peptides anti-microbiens de crustaces
CA2315880A1 (en) * 1997-12-31 1999-07-15 Stressgen Biotechnologies Corporation Streptococcal heat shock proteins of the hsp60 family
EP1049483A1 (en) * 1998-01-23 2000-11-08 National Jewish Medical and Research Center Method for treating inflammatory diseases using heat shock proteins
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
DE69929454T2 (de) * 1998-11-05 2006-09-28 Hadasit Medical Research Services & Development Co. Ltd. Neue aminosäuresequenzen, deren kodierende dns, antikörper dagegen und deren verwendungen
EP1196772A2 (en) * 1999-07-08 2002-04-17 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method

Also Published As

Publication number Publication date
GB2389852B (en) 2005-04-06
GB2390366B (en) 2005-04-13
JP4648956B2 (ja) 2011-03-09
JP2008179646A (ja) 2008-08-07
JP2004513925A (ja) 2004-05-13
JP2004525085A (ja) 2004-08-19
CY1106394T1 (el) 2011-10-12
JP4890733B2 (ja) 2012-03-07
AU1511702A (en) 2002-05-27
JP2008214347A (ja) 2008-09-18
ES2267836T3 (es) 2007-03-16
GB0028122D0 (en) 2001-01-03
AU2002223817A1 (en) 2002-05-27
DE60127159D1 (de) 2007-04-19
CY1105619T1 (el) 2010-12-22
WO2002040517A2 (en) 2002-05-23
GB0311389D0 (en) 2003-06-25
EP1693068B1 (en) 2016-05-04
CA2429897A1 (en) 2002-05-23
ATE355845T1 (de) 2007-03-15
NZ525858A (en) 2005-02-25
NZ525859A (en) 2004-11-26
AU2002215117B2 (en) 2005-05-19
EP1693068A1 (en) 2006-08-23
WO2002040038A3 (en) 2002-10-24
ATE326977T1 (de) 2006-06-15
ES2585641T3 (es) 2016-10-07
CA2429894A1 (en) 2002-05-23
GB2389852A (en) 2003-12-24
EP1333841A2 (en) 2003-08-13
WO2002040037A2 (en) 2002-05-23
WO2002040037A3 (en) 2002-09-06
AU2002215123B2 (en) 2005-05-19
US20040127438A1 (en) 2004-07-01
DE60119959D1 (de) 2006-06-29
HK1060970A1 (en) 2004-09-03
AU1512302A (en) 2002-05-27
DE60119959T2 (de) 2007-01-04
EP1333841B1 (en) 2006-05-24
GB2390366A (en) 2004-01-07
GB0311383D0 (en) 2003-06-25
WO2002040517A3 (en) 2002-09-06
EP1333840B1 (en) 2007-03-07
DK1333841T3 (da) 2006-09-25
EP1333840A2 (en) 2003-08-13
US20040132163A1 (en) 2004-07-08
WO2002040038A2 (en) 2002-05-23
JP2008174565A (ja) 2008-07-31
JP4648955B2 (ja) 2011-03-09
EP1333840B9 (en) 2007-08-29
PT1333841E (pt) 2006-10-31

Similar Documents

Publication Publication Date Title
HK1060521A1 (en) Pharmaceuticals comprising the heat shock protein 10 (cpn 10) from my cobacterium tuberculosis.
EP1832599A3 (en) Albumin fusion proteins
WO2003060071A3 (en) Albumin fusion proteins
ATE532860T1 (de) B7-ähnliche moleküle und deren anwendungen
WO2003030821A3 (en) Albumin fusion proteins
DE60037978D1 (de) Interferon ähnliche moleküle, und deren verwendungen
WO2002102316A3 (en) Histone deacetylase and methods of use thereof
MXPA03010728A (es) Moleculas de proteina-2 relacionadas con b7 y uso de las mismas.
WO2002072632A3 (en) Nucleic acids of the human abcc11 gene, vectors containing such nucleic acids and uses thereof.
WO2003025014A3 (fr) Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes
DE69529235D1 (de) Menschliche dnase i varianten
DE60022069D1 (de) Nicht-anaphylaktische formen des grasspollenallergens ph1 p 6 und deren verwendung
MXPA03010739A (es) Moleculas de marcador endotelial tumoral 7-alfa y uso de las mismas.
WO2002063013A3 (en) Human acid phosphatase gene
WO2003000717A3 (de) Identifizierung von ses-3 (spr-5) aus c. elegans sowie dessen verwendungen
WO2002062845A3 (en) Adhesion molecules
MX9706429A (es) Variantes de dnasa i humana.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20111116